Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 36 Neoplasms 8 Lung Neoplasms 7 Neoplasm Metastasis 4 Neoplasms by Site 3 Lymphoma, Large-Cell, Anaplastic 3 Hematologic Neoplasms 3 Breast Neoplasms 3 Brain Neoplasms 3 Thyroid Neoplasms 2 Sarcoma 2 Pancreatic Neoplasms 2 Ovarian Neoplasms 2 Neoplasms by Histologic Type 2 Lymphoproliferative Disorders 2 Gastrointestinal Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Renal Cell 2 Urinary Bladder Neoplasms 1 Thyroid Cancer, Papillary 1 Thoracic Neoplasms 1 Solid Tumors 1 Sexual Dysfunction, Physiological 1 Salivary Gland Neoplasms 1 Respiratory Tract Neoplasms 1 Respiratory Tract Diseases 1 Rare Tumour 1 Rare Tumor 1 Prostatic Neoplasms 1 Neuroendocrine Tumors 1

Interventions

sintilimab 1 pyrotinib 1 palbociclib 1 niraparib 1 dacomitinib 1 aumolertinib 1 atezolizumab 1 alectinib 1 Vemurafenib 1 Imatinib Mesylate 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Rare Tumor × alectinib × Clear all

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

Rare Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡